Distribution of apolipoprotein A-I, C-II, C-III, and E mRNA in fetal human tissues. Time-dependent induction of apolipoprotein E mRNA by cultures of human monocyte-macrophages.
Distribution of apolipoprotein A-I, C-II, C-III, and E mRNA in fetal human tissues. Time-dependent induction of apolipoprotein E mRNA by cultures of human monocyte-macrophages.
复制标题
载脂蛋白 A-I、C-II、C-III 和 E mRNA 在胎儿人体组织中的分布。
DOI：
10.1021/bi00337a028
复制
发表时间：
1985
期刊：
影响因子：
2.9
通讯作者：
Karathanasis,SK
中科院分区：
文献类型：
--
作者：
Zannis,VI;Cole,FS;Jackson,CL;Kurnit,DM;Karathanasis,SK
最近开发的人类载脂蛋白 (apo) 基因分子探针已用于研究 apo AI、apo C-II、apo C-III 和 apo E 基因的人体组织表达的特异性。我们发现 apo E mRNA 存在于所有检查的组织中。根据总RNA浓度，apo E mRNA的相对丰度以肝脏值的百分比表示如下：肾上腺和巨噬细胞，74-100%；性腺和肾脏，12-15%；脾、脑、胸腺、卵巢、肠和胰腺，3-9%；心脏，1.5%；胃、横纹肌和肺< 1%。人外周血单核巨噬细胞培养物中apo E mRNA的相对浓度随培养时间的变化而急剧增加，5天后与肝脏相比。还检查了显示合成apo E mRNA的人体组织合成apo AI、apo C-II和apo C-III mRNA的能力。以肝脏值的百分比表示的apo AI、apo C-III和apo C-II mRNA的相对丰度如下：apo AI，肠，50%； apo AI、胰腺和性腺，12%； apo AI，肾，4%； apo AI，肾上腺，2.5%； apo AI，卵巢和心脏，1%； apo AI，胃和胸腺，< 1%； apo C-III，肠，62%； apo C-III，胰腺，7%； apo C-II，肠，3%； apo C-II，胰腺，< 1%。了解载脂蛋白合成中的组织特异性对于我们理解载脂蛋白和脂蛋白代谢的调节非常重要。过去五年来，载脂蛋白合成位点的定义一直是广泛研究的主题。基于蛋白质定量技术，哺乳动物的两个器官，即肝脏和肠道，被认为产生了大部分血浆载脂蛋白（Windmueller 等，1973；Marsh，1976；Hamilton 等，1976；Glickman & Green，1977；Green 等，1978；Schonfeld 等，1978；Wu & Windmueller，温德穆勒和吴，1981）。最近，其他组织已被证明可以合成一些载脂蛋白（Blue 等人，1980、1982、1983；Basu 等人，1982）。人类载脂蛋白基因探针的开发（Breslow 等人，1982a，b，1983；Karathanasis 等人，1985；Zannis 等人，1984；Jackson 等人，1984）允许对 f 的量进行定性和定量比较。这项工作得到了美国国立卫生研究院（HL33952、HL32032 和HD00584）、March of Dimes 出生缺陷基金会 (1-817) 和美国心脏协会 (83-963)。 VIZ 是美国心脏协会的资深研究员。
Recently developed molecular probes for human apolipoprotein (apo) genes have been used to study the specificity of human tissue expression of the apo AI, apo C-II, apo C-III, and apo E genes. We have found that apo E mRNA was present in all tissues examined. On the basis of total RNA concentration the relative abundance of apo E mRNA expressed as a percentage of the liver value is as follows: adrenal gland and macrophages, 74-100%; gonads and kidney, 12-15%; spleen, brain, thymus, ovaries, intestine, and pancreas, 3-9%; heart, 1.5%; stomach, striated muscle, and lung,< 1%. The relative concentration of apo E mRNA in cultures of human peripheral blood monocyte-macrophages increases dramatically as a function of time in culture, and after 5 days, it compares to that of liver. The human tissues shown to synthesize apo E mRNA were also examined for their ability to synthesize apo AI, apo C-II, and apo C-III mRNA. The relative abundance of apo AI, apo C-III, and apo C-II mRNA expressed as a percentage of the liver value is as follows: apo AI, intestine, 50%; apo AI, pancreas and gonads, 12%; apo AI, kidney, 4%; apo AI, adrenal, 2.5%; apo AI, ovaries and heart, 1%; apo AI, stomach and thymus,< 1%; apo C-III, intestine, 62%; apo C-III, pancreas, 7%; apo C-II, intestine, 3%; apo C-II, pancreas,< 1%. The knowledge of tissue specificitiesin the synthesis of apolipoproteins is important for our understanding of the regulation of apolipoproteins and lipoprotein metabolism. e definition of the sites of apolipoprotein synthesishas been the subject of extensive investigation during the last five years. On thebasis of protein quantitation techniques, two organs in mammalian species, the liver and the intestine, were thought to produce most of the plasma apolipoproteins (Windmueller et al., 1973; Marsh, 1976; Hamilton et al., 1976; Glickman & Green, 1977; Green et al., 1978; Schonfeld et al., 1978; Wu & Windmueller, 1979; Windmueller & Wu, 1981). Recently, other tissues have been shown to synthesize some of the apolipoproteins (Blue et al., 1980, 1982, 1983; Basu et al., 1982). The development of probes for the human apolipoprotein genes (Breslow et al., 1982a, b, 1983; Karathanasis et al., 1985; Zannis et al., 1984; Jackson et al., 1984) permits a qualitative and quantitative comparison of the amounts of fThis work was supported by grants from the National Institutes of Health (HL33952, HL32032, and HD00584), the March of Dimes Birth Defects Foundation (1-817), and the American Heart Association (83-963). VIZ is an Established Investigator of the AmericanHeart As-sociation.